{
  "nctrialId": "HC-1903",
  "title": "A Randomized Double-Blind, Active-Controlled Multi-Center Study of HFR-841 (SGLT2 inhibitor) in Patients With Irritable Bowel Syndrome",
  "officialTitle": "A Randomized Double-Blind, Active-Controlled Multi-Center Study of HFR-841 (SGLT2 inhibitor) in Patients With Irritable Bowel Syndrome",
  "sponsor": "BC Cancer Agency",
  "indication": "Irritable Bowel Syndrome",
  "phase": "Phase 4",
  "fileName": "HC-1903.json",
  "fileSize": 286649,
  "date": "2024-02-27",
  "completionDate": "2028-02-21",
  "drugName": "HFR-841 (SGLT2 inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Completed",
  "description": "This is a randomized double-blind, active-controlled multi-center study designed to evaluate the efficacy and safety of HFR-841 (SGLT2 inhibitor) in patients with Irritable Bowel Syndrome. The study will enroll approximately 78 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 21-66 years\n- Confirmed diagnosis of Irritable Bowel Syndrome\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}